Weight-Loss Drugs Linked to Rare Brain Disorder

A rare and potentially fatal neurological condition has been spotted in people using weight-loss medications, according to new research. This disorder is known as Wernicke encephalopathy. It strikes the brain with severe confusion and disorientation that keeps getting worse unless treated immediately. The root cause is a shortage of thiamine, or vitamin B1. Humans get this nutrient from meats, fish, and whole grains. Without it, the brain cannot function properly.

Usually, this condition hits middle-aged patients who struggle with alcohol use disorder or have other gut issues that block nutrient absorption. Alcohol interferes with how the body takes in vitamins. But a study by Israeli researchers changed the picture. They found 15 cases among people taking GLP-1 drugs. Eight of those patients were on semaglutide, the active ingredient in Ozempic or Wegovy. Six were using tirzepatide, which powers Zepbound and Mounjaro. One person took liraglutide, the drug behind Saxenda, an older option for weight loss.

The average age of these patients was 59 years old. They had been on the drugs for roughly five months before symptoms appeared. Every single one complained of other issues in their digestive system. Dr Dana Lev, an internal medicine specialist at Sheba Medical Center and the lead author, wrote this warning in the study. "Wernicke encephalopathy is a potentially rare but severe adverse event of [weight loss drug] treatment," he stated. He added that early detection could stop the disease from spreading. Because of this, doctors need to stay sharp, especially with patients facing serious gastrointestinal trouble.

The researchers only found an association. The data does not prove that these drugs cause the disorder directly. Still, it serves as a warning signal for clinicians who must watch for this condition in their clinics. Most reports came from the FDA's Adverse Event Reporting System. This database lets anyone submit a report on suspected side effects. Those entries remain unverified because they lack proof. The system acts as a crude early alert rather than a final verdict.

Published in the journal Clinical Nutrition, the study listed specific symptoms before diagnosis. Difficulty walking and confusion showed up in seven patients each. Abnormal mental status and paralysis or weakness of eye muscles appeared in three cases each. Before doctors diagnosed them, six people suffered from vomiting. Five had decreased appetite and malnutrition. Three experienced gastroparesis, a condition that paralyzes the stomach. Almost all these reports came during 2023 to 2024. The link between vitamin B1 deficiency and brain failure remains clear.

One incident surfaced during the reporting year spanning 2017 and 2018. Ten additional cases were logged in the United States, while two each appeared in Europe and Asia, with a single report coming from South America. Of the nine patients for whom prescription details existed, four had been given weight loss medications to manage diabetes, three took them solely for losing pounds, and two received prescriptions covering both purposes. Eight reports originated from clinicians, four came from healthcare providers, and three were filed by consumer attorneys. Researchers could not pinpoint exactly what triggered the condition in these patients, yet they suggested a link to nutritional deficiencies. They wrote: 'The prominent weight loss associated with [weight loss drug] treatments alongside the relatively frequent gastrointestinal side effects provides a biologically plausible basis for our findings and suggests increased susceptibility to nutritional deficiencies, including thiamine depletion.' Vitamin B1 is essential for bodily function, but humans cannot manufacture it; we must rely on animal and plant sources. Almost everyone gets enough from a standard diet, yet users of weight loss drugs often eat significantly less than others, putting them at risk for vitamin and mineral shortages. They may also suffer gastrointestinal issues that block nutrient absorption or vomit regularly, which further cuts down the vitamins their bodies can take in, heightening the danger of deficiencies. Wernicke encephalopathy has already been tied to patients who undergo bariatric surgery, a procedure that can cause malnutrition because a patient cannot eat standard meals for six to eight weeks afterward. Estimates suggest up to 18 percent of bariatric surgery patients develop some degree of vitamin B1 deficiency, raising the risk of suffering from this neurological condition. Scientists noted, however, that these 15 cases among weight loss drug users were reported out of the millions already taking the medication. Estimates suggest 30 million Americans have used a weight loss drug at least once to date, equivalent to 11 percent of the population. Doctors say people with Wernicke encephalopathy have three main symptoms: confusion, inability to coordinate movements and visual changes. If these symptoms are left untreated, they cause lasting damage to brain and nerve cells, leading to a second condition, Korsakoff syndrome, which causes severe memory loss and the inability to form new memories. The condition is fatal because it raises the risk of injury and incapacity, which can be life-threatening. It also leaves an individual unable to look after themselves. Studies suggest up to two percent of people worldwide suffer from Wernicke encephalopathy, although it isn't clear how many people may have the condition in the US. Doctors can slowly reverse symptoms of the condition by administering vitamin B1 as pill supplements or injections. If someone has suffered brain damage already due to the condition, however, they will not be able to completely cure the condition. Counseling for alcohol use disorder or nutritional support can help to prevent the disease.